Peptide library / Heart & blood / Enlicitide
Enlicitide
An investigational oral PCSK9 inhibitor from Merck that sharply lowers LDL cholesterol.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Lower LDL cholesterolLarge trials
- Cardiovascular eventsLarge trials
How it is thought to work
Enlicitide is a macrocyclic peptide taken as a daily pill. It blocks PCSK9, so the liver clears more LDL cholesterol.
What the evidence shows
Phase 3 trials reported LDL reductions of roughly half or more compared with placebo. An outcomes trial is ongoing.
Safety and unknowns
Similar side effect rates to placebo in trials so far.
Regulatory status
Not approved at the time of writing. Check the FDA database for the latest.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Heart & blood
Eptifibatide
FDA-approvedA cyclic peptide platelet blocker modeled on rattlesnake venom, used in acute coronary syndromes.
Icatibant
FDA-approvedA ten amino acid bradykinin blocker for attacks of hereditary angioedema.
Elamipretide
FDA-approvedA four amino acid peptide that targets mitochondria, approved in 2025 for Barth syndrome.
General information, not medical advice. Do not buy or inject unregulated peptides.